Vicore Pharma (JTGEY) F-6/A registers 500M ADSs at $5.00 each

Rhea-AI Filing Summary

Vicore Pharma Holding AB amended its Form F-6 registration to correct the cover page and restate that a separate registration statement has been filed for the deposited shares. The amendment registers 500,000,000 American Depositary Shares (ADSs), each ADS representing the right to receive ten (10) common shares, at a proposed maximum offering price of $5.00 per ADS and a proposed maximum aggregate offering price of $25,000,000. The filing is a pre-effective amendment executed on June 9, 2026 and names Citibank, N.A. as depositary.

Insights

Capital Markets Attorney

Registration fixes cover language; standard Form F-6 mechanics.

The amendment corrects the prospectus cover and reconfirms registration of 500,000,000 ADSs at a proposed maximum aggregate price of $25,000,000. It is a procedural filing under Rule 478(a) and Rule 466 and does not change substantive terms.

Key dependencies include the separate registration statement referenced and the deposit agreement previously filed on May 22, 2026. Subsequent filings will show if and when the registration becomes effective.

Depositary / Equity Structure Specialist

ADS structure: one ADS = ten underlying shares; Citibank acts as depositary.

The document specifies that each ADS represents the right to ten common shares and lists Citibank, N.A. as depositary and Vicore Pharma US, Inc. as U.S. agent. The prospectus is the form of American Depositary Receipt incorporated by reference to the Deposit Agreement.

Practical items to watch in future filings include effectiveness status and any pricing or distribution details for the ADSs.

Key Figures

ADS registered: 500,000,000 ADSs ADS ratio: 1 ADS = 10 common shares Proposed maximum price per ADS: $5.00 +4 more

7 metrics

ADS registered 500,000,000 ADSs Registration on Form F-6/A

ADS ratio 1 ADS = 10 common shares Terms of deposit stated in prospectus

Proposed maximum price per ADS <money>$5.00</money> Calculation of Registration Fee table

Proposed maximum aggregate offering price <money>$25,000,000</money> Calculation of Registration Fee table

Registration fee <money>$3,452.50</money> Amount of Registration Fee shown on cover

Deposit agreement filing date May 22, 2026 Form of Deposit Agreement previously filed

Amendment execution date June 9, 2026 Signatures block for the Pre-Effective Amendment

Key Terms

American Depositary Share (ADS), Form F-6, Deposit Agreement, Rule 478(a) / Rule 466

4 terms

American Depositary Share (ADS) financial

"American Depositary Shares (ADSs), each ADS representing the right to receive ten (10) common shares"

Form F-6 regulatory

"Pre-Effective Amendment No. 1 to the Registration Statement on Form F-6"

Form F-6 is an SEC registration form used when a U.S. depositary bank creates American Depositary Receipts (ADRs), which are certificates that let U.S. investors buy and sell shares of a foreign company as if they were domestic stocks. Think of an ADR as a local-language label placed on a foreign product: it makes the foreign share easier to trade and settle in U.S. markets, increasing accessibility, liquidity and investor choice while bringing certain U.S. disclosure and regulatory oversight.

Deposit Agreement legal

"Form of Deposit Agreement, previously filed with the Commission on May 22, 2026"

A deposit agreement is a written contract between a customer and a financial institution that outlines the terms for opening and maintaining a deposit account, such as a savings or checking account. It explains important details like how funds can be accessed, any fees involved, and the institution’s responsibilities. For investors, understanding this agreement is important because it clarifies their rights and the rules governing their deposited funds.

Rule 478(a) / Rule 466 regulatory

"filed pursuant to Rule 478(a) ... It is proposed that this filing become effective under Rule 466"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

As filed with the Securities and Exchange Commission on June 9, 2026 Registration No. 333-296169

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________________________

PRE-EFFECTIVE AMENDMENT NO. 1 TO THE
FORM F-6
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY
AMERICAN DEPOSITARY RECEIPTS

____________

VICORE PHARMA HOLDING AB

(Exact name of issuer of deposited securities as specified in its charter)

____________

N/A

(Translation of issuer’s name into English)

____________

Kingdom of Sweden

(Jurisdiction of incorporation or organization of issuer)

________________________________

CITIBANK, N.A.

(Exact name of depositary as specified in its charter)

____________

388 Greenwich Street

New York, New York 10013

(877) 248-4237

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

____________

Vicore Pharma US, Inc.

One Broadway

14th Floor

Cambridge, MA 02142, USA

(Address, including zip code, and telephone number, including area code, of agent for service)

________________________________

Copies to:

William C. Hicks, Esq. John T. Rudy, Esq. Allyson Wilkinson, Esq. Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 (617) 348-3050 Jason W. Parsont, Esq. Mayer Brown LLP 1221 Avenue of the Americas New York, New York 10020 (212) 506-2500

It is proposed that this filing become effective under Rule 466:	☐ immediately upon filing.
	☐ on (Date) at (Time).
If a separate registration statement has been filed to register the deposited shares, check the following box: ☒

________________________________

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Amount to be Registered	Proposed Maximum Aggregate Price Per Unit*	Proposed Maximum Aggregate Offering Price**	Amount of Registration Fee
American Depositary Shares (ADS(s)), each ADS representing the right to receive ten (10) common shares of Vicore Pharma Holding AB (the “Company”)	500,000,000 ADSs	$5.00	$25,000,000	$3452.50***

* Each unit represents 100 ADSs.

** Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

***	Previously paid.
	The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.
	This Pre-Effective Amendment No. 1 to the Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

EXPLANATORY NOTE

This Pre-Effective Amendment No. 1 to the Registration Statement is filed pursuant to Rule 478(a) under the Securities Act of 1933, as amended, solely to correct the cover page to indicate by check mark that a separate registration statement has been filed to register the deposited shares. No changes have been made to the Registration Statement other than this explanatory note.

PART I

INFORMATION REQUIRED IN PROSPECTUS

Cross Reference Sheet

Item 1. DESCRIPTION OF SECURITIES TO BE REGISTERED

Item Number and Caption			Location in Form of American Depositary Receipt (“Receipt”) Filed Herewith as Prospectus
1.	Name of Depositary and address of its principal executive office		Face of Receipt - Introductory Article.
2.	Title of Receipts and identity of deposited securities		Face of Receipt - Top Center.
Terms of Deposit:
(i)	The amount of deposited securities represented by one American Depositary Share (“ADSs”)		Face of Receipt - Upper right corner.
(ii)	The procedure for voting, if any, the deposited securities		Reverse of Receipt - Paragraphs (17) and (18).
(iii)	The collection and distribution of dividends		Reverse of Receipt - Paragraph (15).
(iv)	The transmission of notices, reports and proxy soliciting material		Face of Receipt - Paragraph (14); Reverse of Receipt - Paragraph (18).
(v)	The sale or exercise of rights		Reverse of Receipt - Paragraphs (15) and (17).
(vi)	The deposit or sale of securities resulting from dividends, splits or plans of reorganization		Face of Receipt - Paragraphs (3) and (6); Reverse of Receipt - Paragraphs (15) and (17).
(vii)	Amendment, extension or termination of the deposit agreement		Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
(viii)	Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs		Face of Receipt - Paragraph (14).
(ix)	Restrictions upon the right to deposit or withdraw the underlying securities		Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10).
(x)	Limitation upon the liability of the Depositary		Face of Receipt - Paragraph (8); Reverse of Receipt - Paragraphs (20) and (21).
3.	Fees and charges which may be imposed directly or indirectly on holders of ADSs		Face of Receipt - Paragraph (11).

I-1 

Item 2. AVAILABLE INFORMATION Face of Receipt - Paragraph (14).

The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

I-2 

PROSPECTUS

The Prospectus consists of the proposed form of American Depositary Receipt included as Exhibit A to the Form of Deposit Agreement filed as Exhibit (a) to the Registration Statement on Form F-6, filed on May 22, 2026, and is incorporated herein by reference.

I-3 

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 3. EXHIBITS

(a) Form of Deposit Agreement, by and among Vicore Pharma Holding AB (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ^___ Previously filed with the Commission on May 22, 2026 as Exhibit (a) to the Registration Statement on Form F-6 (File No. 333-296169), and incorporated herein by reference.

(b) Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ^___ None.

(c) Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ^___ None.

(d) Opinion of counsel for the Depositary as to the legality of the securities to be registered. ^___ Previously filed with the Commission on May 22, 2026 as Exhibit (d) to the Registration Statement on Form F-6 (File No. 333-296169), and incorporated herein by reference.

(e) Certificate under Rule 466. ^___ None.

(f) Powers of Attorney for certain officers and directors and the authorized representative of the Company. ^___ Set forth on the signature pages to the Registration Statement on Form F-6 (File No. 333-296169) filed with the Commission on May 22, 2026, and incorporated herein by reference.

Item 4. UNDERTAKINGS

(a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADRs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

(b) If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADR thirty (30) days before any change in the fee schedule.

II-1 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity to be created by the Deposit Agreement, by and among Vicore Pharma Holding AB, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to the Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on June 9, 2026.

Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder
are to be issued, each American Depositary Share representing the right to receive ten (10) common shares of Vicore Pharma Holding AB.

CITIBANK, N.A., solely in its capacity as Depositary
By:	/s/ Leslie DeLuca
	Name: Leslie DeLuca
	Title: Attorney-in-fact

II-2 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Vicore Pharma Holding AB, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Pre-Effective Amendment No. 1 to the Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Brookline, Massachusetts, United States on June 9, 2026.

VICORE PHARMA HOLDING AB
By:	/s/ Ahmed Mousa
	Name: Ahmed Mousa
	Title: Chief Executive Officer

II-3 

Pursuant to the requirements of the Securities Act of 1933, as amended, this Pre-Effective Amendment No. 1 to the Registration Statement on Form F-6 has been signed by the following persons in the following capacities on June 9, 2026.

Signature		Title
*		Chief Executive Officer (Principal Executive Officer)
Ahmed Mousa
*		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
Hans Jeppsson
*		Chairman
Hans Schikan
*		Director
Jacob Gunterberg
*		Director
Heidi Hunter
*		Director
Elisabeth Björk
*		Director
Ann Barbier
*		Director
Yasir Al-Wakeel
*		Director
Peter Guenter

*By:	/s/ Ahmed Mousa
	Attorney-in-fact

II-4 

SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT

Under the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America, has signed this Pre-Effective Amendment No. 1 to Registration Statement on Form F-6 in Brookline, Massachusetts, United States, on June 9, 2026.

Authorized Representative in the United States
By:	/s/ Ahmed Mousa
	Name: Ahmed Mousa
	Title: Chief Executive Officer

II-5 

Index to Exhibits

Exhibit	Document	Sequentially Numbered Page
(a)	Form of Deposit Agreement, previously filed with the Commission on May 22, 2026 as Exhibit (a) to the Registration Statement on Form F-6 (File No. 333-296169), and incorporated herein by reference.
(d)	Opinion of counsel to the Depositary, previously filed with the Commission on May 22, 2026 as Exhibit (d) to the Registration Statement on Form F-6 (File No. 333-296169), and incorporated herein by reference.

II-6

FAQ

What does Vicore Pharma's Form F-6/A register (JTGEY)?

It registers 500,000,000 ADSs, each ADS representing the right to receive ten common shares. The filing lists a proposed maximum aggregate offering price of $25,000,000 at $5.00 per ADS.

Who is the depositary for Vicore Pharma ADSs (JTGEY)?

The depositary named is Citibank, N.A.. Citibank is listed as the entity to issue ADSs under the Deposit Agreement and is identified on the face of the Receipt as the depositary.

Why was this Pre-Effective Amendment filed for Vicore Pharma (JTGEY)?

The amendment was filed pursuant to Rule 478(a) to correct the cover page to indicate that a separate registration statement has been filed to register the deposited shares. No other substantive changes were made.

When was the Vicore Pharma Form F-6/A signed and by whom?

The Pre-Effective Amendment was executed on June 9, 2026 and signed on behalf of the registrant by Ahmed Mousa, Chief Executive Officer, and by Leslie DeLuca as attorney-in-fact for Citibank, N.A.